Trials / Completed
CompletedNCT03190616
Apatinib in Refractory Colorectal Cancer
A Single Arm, Open Label, Multicenter Exploratory Study of Apatinib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Second Line Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Limited agents have been approved after standard first and second line treatment. Regorafenib and Trifluridine/Tipiracil (TAS-102) are still not approved in China.Apatinib has shown significant efficacy in refractory advanced gastric cancer regarding PFS and OS with controllable toxicity.This study is aimed to explore the efficacy,safety as well as predictive biomarker in advanced colorectal cancer failed to standard therapy in Chinese population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | apatinib | apatinib 500mg/qd, 28d/cycle |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2019-06-30
- Completion
- 2019-12-30
- First posted
- 2017-06-19
- Last updated
- 2020-01-14
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03190616. Inclusion in this directory is not an endorsement.